The results of the RIMDAMAL trial in Burkina Faso, reported by Brian Foy and colleagues, show that repeated mass treatment with ivermectin can reduce the incidence of malaria in children aged 5 years or younger, with no serious adverse effects. but, as far as we know, none is targeting an onchocerciasis-endemic region with high ongoing In the roadmap to deploy ivermectin as a malaria prevention tool, similar trials are ongoing or plannedOnchocerca volvulus transmission.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile